41 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 This first part of the investment, exceeding €60 million, goes beyond a single unit design and is setting up PROCOS for the future. Along with the previous land expansion from 135.000 square metres to 155.000 square metres, R11 is furnished with additional auxiliary services and allocations to quickly increase capacity and respond immediately to market and customer needs. This even more customeroriented approach will allow the company to design and build up rigs in a relatively short time that could be perfectly tailored for specific customer needs and to potentially expand into a new business area (e.g. new modality programs). It believes this philosophy is what customers expect from a long-term CDMO partner. R11 also represents PROCOS’ ability to constantly grow while remaining faithful to its core values of quality, knowledge and partnership and the long-term vision for prosperity and continuity. These are the key pillars of the strong synergy between PROCOS and the CBC Group of Japan, marking 20 years since it became part of the Group – a shared legacy of success that combines Italian industrial expertise with a broader international vision inspired by Japanese innovation and long-term strategy. Today, PROCOS reinforces its role as a dependable and future-oriented CDMO, equipped to address the increasing complexity of pharmaceutical development and manufacturing. Through sustained investment, technological excellence and a strong commitment to sustainability, the company continues to build long-term value for customers and partners worldwide. PROCOS SIMONE MANZINI Business Development Manager, Custom Sinthesys Procos SpA (CBC Group)
RkJQdWJsaXNoZXIy MjY2OTA4MA==